



# Atrial Transcriptional Profiles of Molecular Targets Mediating Electrophysiological Function in Aging and *Pgc-1β* Deficient Murine Hearts

Charlotte E. Edling<sup>1</sup>, Ibrahim T. Fazmin<sup>1,2</sup>, Karan R. Chadda<sup>1,2</sup>, Shiraz Ahmad<sup>2</sup>, Haseeb Valli<sup>2</sup>, Christopher L.-H. Huang<sup>2,3</sup> and Kamalan Jeevaratnam<sup>1,2,4\*</sup>

<sup>1</sup> Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom, <sup>2</sup> Physiological Laboratory, University of Cambridge, Cambridge, United Kingdom, <sup>3</sup> Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom, <sup>4</sup> School of Medicine, Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia

## OPEN ACCESS

### Edited by:

Ruben Coronel,  
University of Amsterdam, Netherlands

### Reviewed by:

Wayne Rodney Gilles,  
University of Calgary, Canada

Gary Tse,  
The Chinese University of Hong Kong,  
China

Bas J. Boukens,  
University of Amsterdam, Netherlands

### \*Correspondence:

Kamalan Jeevaratnam  
drkamalanjeeva@gmail.com

### Specialty section:

This article was submitted to  
Cardiac Electrophysiology,  
a section of the journal  
Frontiers in Physiology

Received: 03 October 2018

Accepted: 08 April 2019

Published: 24 April 2019

### Citation:

Edling CE, Fazmin IT, Chadda KR, Ahmad S, Valli H, Huang CL-H and Jeevaratnam K (2019) Atrial Transcriptional Profiles of Molecular Targets Mediating Electrophysiological Function in Aging and *Pgc-1β* Deficient Murine Hearts. *Front. Physiol.* 10:497. doi: 10.3389/fphys.2019.00497

**Background:** Deficiencies in the transcriptional co-activator, peroxisome proliferative activated receptor, gamma, coactivator-1β are implicated in deficient mitochondrial function. The latter accompanies clinical conditions including aging, physical inactivity, obesity, and diabetes. Recent electrophysiological studies reported that *Pgc-1β*<sup>-/-</sup> mice recapitulate clinical age-dependent atrial pro-arrhythmic phenotypes. They implicated impaired chronotropic responses to adrenergic challenge, compromised action potential (AP) generation and conduction despite normal AP recovery timecourses and background resting potentials, altered intracellular Ca<sup>2+</sup> homeostasis, and fibrotic change in the observed arrhythmogenicity.

**Objective:** We explored the extent to which these age-dependent physiological changes correlated with alterations in gene transcription in murine *Pgc-1β*<sup>-/-</sup> atria.

**Methods and Results:** RNA isolated from murine atrial tissue samples from young (12–16 weeks) and aged (>52 weeks of age), wild type (WT) and *Pgc-1β*<sup>-/-</sup> mice were studied by pre-probed quantitative PCR array cards. We examined genes encoding sixty ion channels and other strategic atrial electrophysiological proteins. *Pgc-1β*<sup>-/-</sup> genotype independently reduced gene transcription underlying Na<sup>+</sup>-K<sup>+</sup>-ATPase, sarcoplasmic reticular Ca<sup>2+</sup>-ATPase, background K<sup>+</sup> channel and cholinergic receptor function. Age independently decreased Na<sup>+</sup>-K<sup>+</sup>-ATPase and fibrotic markers. Both factors interacted to alter *Hcn4* channel activity underlying atrial automaticity. However, neither factor, whether independently or interactively, affected transcription of cardiac Na<sup>+</sup>, voltage-dependent K<sup>+</sup> channels, surface or intracellular Ca<sup>2+</sup> channels. Nor were gap junction channels, β-adrenergic receptors or transforming growth factor-β affected.

**Conclusion:** These findings limit the possible roles of gene transcriptional changes in previously reported age-dependent pro-arrhythmic electrophysiological changes

observed in *Pgc-1 $\beta$ <sup>-/-</sup>* atria to an altered Ca<sup>2+</sup>-ATPase (*Atp2a2*) expression. This directly parallels previously reported arrhythmic mechanism associated with p21-activated kinase type 1 deficiency. This could add to contributions from the direct physiological outcomes of mitochondrial dysfunction, whether through reactive oxygen species (ROS) production or altered Ca<sup>2+</sup> homeostasis.

**Keywords:** peroxisome proliferator activated receptor- $\gamma$  (PPAR $\gamma$ ), coactivator-1 transcriptional coactivator (*Pgc-1*), quantitative PCR, ion channels, mitochondria, arrhythmias

## INTRODUCTION

Atrial arrhythmias constitute a major public health problem. Atrial fibrillation (AF), affects 1–3% of the developed world population. This prevalence will likely increase to ~9 and ~18 million cases in the United States and Europe, respectively, by 2060 (Miyasaka et al., 2006). Chronic AF increases incidences of both morbidity, often as stroke, and all-cause mortality.

Age is a major risk factor for AF, affecting 0.1, 4, and 20% of individuals aged <55, 60–70 and >80 years, respectively. So are metabolic factors, arising from physical inactivity, obesity, diabetes mellitus, and metabolic syndrome. Themselves age-dependent, these account for ~60% of current upward trends in AF incidence (Miyasaka et al., 2006). Both age and metabolic deficiency in turn are associated with mitochondrial dysfunction (Vianna et al., 2006). Age is associated with mitochondrial DNA damage and compromised respiratory chain function (Krishnan et al., 2007); obese mice on high fat diets show defective mitochondrial electron transport chain complex I (Wang X. et al., 2015).

Acute and chronic mitochondrial dysfunction have cardiac pro-arrhythmic effects (Akar and O'Rourke, 2011). This indicates abnormalities in one or more of the ordered processes of action potential (AP) initiation, recovery, excitation and propagation. These in turn would reflect altered ion channel function or expression or structural, fibrotic or cardiomyopathic change altering AP conduction, findings reported in experimental diabetes (Russo and Frangogiannis, 2016) and metabolic syndrome (Ho et al., 2017).

Peroxisome proliferator activated receptor- $\gamma$  (PPAR $\gamma$ ) and coactivator-1 transcriptional coactivators (*Pgc-1*) are important cellular energetic regulators. They are abundant in oxidative tissues, including cardiac and skeletal muscle, and brown adipose tissue (Sonoda et al., 2007). They regulate mitochondrial biogenesis and mass (Villena, 2015). They also influence mitochondrial function, increasing expression of genes related to fatty acid  $\beta$ -oxidation, the tricarboxylic acid cycle and electron transport (Arany et al., 2005). Their expression is impaired in metabolic conditions including obesity, insulin resistance, type 2 diabetes and in first-degree relatives of diabetic patients (Scheuermann-Freestone et al., 2003). *Pgc-1 $\alpha$*  levels respond to physiological stimuli such as fasting, exercise and cold temperatures, adapting tissues to changes in energy demand. *Pgc-1 $\beta$*  appears involved in baseline energetic balance (Villena, 2015).

Finally, *Pgc-1 $\alpha$* , and *Pgc-1 $\beta$* -deficient murine experimental models replicate clinically observed atrial pro-arrhythmic

effects of energetic deficiencies. Recent reports implicated age-dependent impairments in chronotropic adrenergic responses, AP generation and conduction despite normal AP recoveries and background resting potentials. They also demonstrated altered intracellular Ca<sup>2+</sup> homeostasis and fibrotic change (Gurung et al., 2011; Ahmad et al., 2018; Valli et al., 2017a,b, 2018a).

The present studies now explore for transcriptional alterations in the genes encoding the underlying electrophysiological mechanisms in atria of the *Pgc-1 $\beta$* -deficient mice (Komen and Thorburn, 2014). Genes were selected and grouped according to the physiological processes underlying different physiological aspects of excitable activity (Huang, 2017). This adapts an approach first applied to rat as opposed to genetically modified mouse hearts (Atkinson et al., 2013). This would make it possible to determine the extent to which previously reported pro-arrhythmic changes reflect altered gene transcription, or whether they more likely follow alterations in subsequent stages in gene expression or even altered function in their resulting proteins.

## MATERIALS AND METHODS

### Animals

Experiments were approved by the University of Cambridge ethics review board under a United Kingdom project license for studies of cardiac arrhythmia. All procedures complied with United Kingdom Home Office regulations [Animals (Scientific Procedures) Act 1986]. The experiments also conformed to the Guide for the Care and Use of Laboratory Animals, United States National Institutes of Health (NIH Publication No. 85-23, revised 1996). Mice were housed in an animal facility at 21°C with 12-h light/dark cycles. Animals were fed sterile chow (RM3 Maintenance Diet, SDS, Witham, Essex, United Kingdom) and had free access to water, bedding and environmental stimuli. Mice were sacrificed by cervical dislocation. No recovery, anesthetic or surgical procedures were required. Wild Type (WT) C57/B6 and *Pgc-1 $\beta$ <sup>-/-</sup>* (The Jackson Laboratory, ME, United States) mice were bred for the experimental protocols. Mice were bred on a C57/B6 background to avoid possible strain-related confounds.

### Tissue Samples

Hearts were obtained from four experimental groups, respectively, consisting of young WT, young *Pgc-1 $\beta$ <sup>-/-</sup>*, aged WT, and aged *Pgc-1 $\beta$ <sup>-/-</sup>* mice. Three hearts were studied from each group. The mice studied were littermates of animals whose hearts had undergone electrophysiological study reported

elsewhere (Valli et al., 2017a,b, 2018a,b). Young mice were between the ages of 12–16 weeks old and aged mice greater than 52 weeks of age. After extraction, the heart was cut to separate the atria tissue from the ventricular tissue and both parts were subsequently snap frozen.

## Taqman Array Assay

RNA was extracted from fresh frozen tissues, stored in  $-80^{\circ}\text{C}$ , with the Qiagen RNeasy mini Plus kit. Cardiac atrial tissue were weighed and put on ice and subsequently homogenized in RLT buffer supplemented with beta-mercaptoethanol with a Stuart handheld homogenizer until completely smooth. Genomic DNA was eliminated by centrifugation through a column supplied with the kit prior to extraction of the RNA according to the manufacturer's protocol. RNA integrity was assessed by using an Agilent bioanalyzer to obtain RNA integrity numbers (RIN) according to the manufacturer's protocol. RNA samples with RINs above 8 were used for the study. The RNA was used to prepare cDNA with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. The efficiency of the cDNA protocol was tested by preparing the cDNA from a serial dilution of the RNA and then these cDNA samples were run on a qPCR confirming equal efficiency over a range of RNA concentrations. cDNA was also confirmed negative for genomic DNA contamination. Each custom made card contained 64 pre-validated assays in triplicate with a reaction volume of  $1\ \mu\text{l}$ . The cards were run exactly according to instructions specific for the cards. Briefly, the cDNA (100 ng/well) was mixed with  $2\times$  Mastermix from Thermo Fisher Scientific,  $100\ \mu\text{l}$  was loaded in each well slot on the cards. The cards were then spun down and sealed and run on a Quant 7 cyler. The amplification conditions were:  $50^{\circ}\text{C}$  for 2 min and  $95^{\circ}\text{C}$  for 10 min for the initial DNA melting and inactivation of the RT reaction, followed by 40 cycles of  $95^{\circ}\text{C}$  for 15 s and  $60^{\circ}\text{C}$  for 60 s. Analysis of the Taqman array card data was performed by using the Quant studio software and Microsoft Excel by calculating fold changes with the ddCT method as described by Livak and Schmittgen (2001). The threshold was set at 0.2 fluorescence units and the baseline range was set to automatic assignment. The geometric mean of the Cq values for the genes *HPRT*, *Gapdh*, and *ActinB* were used as references. *P*-values were calculated using two-way analysis of variance (ANOVA) and Student's independent *t*-tests.

## RESULTS

The studies explored transcription profiles in atria of young and aged, WT and *Pgc-1 $\beta$ <sup>-/-</sup>* murine hearts previously demonstrated to recapitulate cardiac pro-arrhythmic phenotypes associated with energetic deficiency. Quantitative PCR evaluated transcriptional backgrounds for genes strategic to pro-arrhythmic electrophysiological phenotypes that might in turn constitute potential pharmacological targets (Komen and Thorburn, 2014). Genes were selected and grouped according to the component physiological processes

underlying excitable activity leading to arrhythmia (Huang, 2017), adapting approaches introduced in rat hearts (Atkinson et al., 2013). Samples obtained by isolating RNA from murine atrial tissue were studied by qPCR using Thermo Fisher Scientific custom Taqman array cards pre-probed with the 60 different genes of potential interest for cardiac function.

Gene transcription fold changes were normalized to levels for the gene in question in young WT mice (Livak and Schmittgen, 2001). **Table 1** lists the genes and the gene expression results obtained, and **Figure 1** overviews expression patterns of relative effect sizes and the directions of the observed differences; red backgrounds indicate increased and green decreased expression relative to young WT. Their intensities are scaled to the highest values (darkest red) and lowest values (darkest greens) of the entire set of genes represented in the map with yellow in the middle indicating an absence or little change. These results are accompanied by the results of a two-way analysis of variance testing for independent and interacting effects of genotype and of age to a  $P < 0.05$  significance level. Effects of age and genotype were sorted by functional gene group corresponding to the physiological processes described in previous reports on *Pgc-1 $\beta$ <sup>-/-</sup>* phenotypes. Control inclusion of *Ppargc1b* transcription levels confirmed highly significant independent effects of genotype.

Of genes related to (1) the energetically dependent  $\text{Na}^+$ - $\text{K}^+$ -ATPase-mediated membrane transport required to generate ionic gradients upon which excitable activity depends and (2) background  $\text{K}^+$  channels mediating the resting potential, we tested transcription activity for  $\text{Na}^+$ - $\text{K}^+$  ATPase  $\alpha_1$  and  $\alpha_2$  catalytic and accessory  $\beta_1$  subunits (encoded by *Atpa1*, *Atpa2*, and *Atpb1*, respectively), the ATP-sensitive inward rectifier  $\text{K}^+$  channel Kir2.2 (*Kcnj12*) coupling resting potentials to intracellular nucleotide levels (Nichols, 2006), and the ATP-binding cassette (ABC) transporter subunits members 8 and 9 (*Abcc8* and *Abcc9*), inwardly rectifying pore-forming  $\text{K}^+$  channels Kir6.1, Kir6.2, and Kir3.1 (*Kcnj8*, *Kcnj11*, and *Kcnj3*) and G protein-activated inward rectifier potassium channel 4, Kir3.4 (*Kcnj5*). The two-way ANOVA suggested independent effects of genotype decreasing *Atp1a1*, *Atp1a2*, *Atp1b1*, *Kcnj8*, and *Abcc9* transcription, and independent effects of age decreasing *Abcc9* transcription.

Of (3) voltage-dependent activating processes, the two-way ANOVA suggested independent effects of genotype decreasing *Scn7a* and interacting effects of genotype and age altering expression of *Hcn4* known to mediate hyperpolarization-activated cyclic nucleotide-gated channels underlying SAN pacemaker currents  $I_f$  (Thollon et al., 2007). It did not detect altered transcription of the major, *Scn5a*, isoform concerned with cardiac  $\text{Na}^+$  current. Nor did the two-way ANOVA demonstrate either independent or interacting effects of genotype and age on (4) the surface membrane voltage-dependent L-type  $\text{Ca}^{2+}$  channels Cav1.2 and Cav1.3 (*Cacna1c* and *Cacna1d*), T-type, Cav3.1 (*Cacna1g*), and Cav3.2 (*Cacna1h*), and the accessory  $\beta_2$  (*Cacnb2*),  $\alpha_2/\delta_1$  (*Cacna2d1*) and  $\alpha_2/\delta_2$  subunits (*Cacna2d2*). Of (5) molecules related to intracellular  $\text{Ca}^{2+}$  homeostasis

**TABLE 1** | Gene groups examined for transcriptional changes by Taqman PCR in WT and *Pgc-1β*<sup>-/-</sup> murine atria.

	gene	WT		WT		<i>Pgc-1β</i> <sup>-/-</sup>		<i>Pgc-1β</i>	
		Young		Old		Young		Old	
		mean	+/- sem	mean	+/- sem	mean	+/- sem	mean	+/- sem
Na <sup>+</sup> -K <sup>+</sup> ATPase activity	Atp1a1	1.00	0.07	1.03	0.11	0.72	0.11	0.82	0.09
	Atp1a2	1.00	0.29	1.37	0.24	0.47	0.08	0.70	0.26
	Atp1b1	1.00	0.22	0.94	0.13	0.59	0.04	0.71	0.09
Ion channels relating to the resting membrane potential	Kcnj12	1.00	0.20	0.93	0.20	0.88	0.08	0.96	0.34
	Abcc8	1.00	0.17	1.10	0.05	0.76	0.14	0.82	0.21
	Abcc9	1.00	0.12	1.69	0.21	0.54	0.01	0.76	0.27
	Kcnj8	1.00	0.13	0.79	0.17	0.49	0.08	0.66	0.04
	Kcnj11	1.00	0.13	0.86	0.06	0.77	0.05	0.87	0.05
	Kcnj3	1.00	0.18	0.81	0.11	0.79	0.03	0.78	0.08
	Kcnj5	1.00	0.10	1.00	0.12	0.83	0.01	1.02	0.15
	Clcn3	1.00	0.09	0.93	0.11	0.86	0.04	0.93	0.07
Ion channels relating to the initiation of excitable activity	Hcn1	1.00	0.04	0.57	0.16	1.70	0.69	0.54	0.05
	Hcn3	1.00	0.24	1.56	0.34	2.42	1.77	0.94	0.45
	Hcn4	1.00	0.43	0.32	0.03	0.52	0.23	1.51	0.41
	Scn5a	1.00	0.15	0.69	0.19	0.72	0.11	0.68	0.08
	Scn7a	1.00	0.13	0.88	0.21	0.49	0.10	0.62	0.06
Ca <sup>2+</sup> homeostasis – surface	Cacna1c	1.00	0.15	0.80	0.13	0.71	0.08	0.79	0.16
	Cacna1d	1.00	0.11	0.85	0.17	0.98	0.29	0.77	0.14
	Cacna1g	1.00	0.30	0.85	0.09	0.85	0.20	1.12	0.48
	Cacna1h	1.00	0.13	1.13	0.14	0.70	0.09	1.05	0.15
	Cacnb2	1.00	0.20	1.46	0.34	0.95	0.14	0.87	0.09
	Cacna2d1	1.00	0.12	1.13	0.12	0.84	0.09	1.10	0.15
	Cacna2d2	1.00	0.41	0.82	0.24	0.92	0.13	1.28	0.12
Ca <sup>2+</sup> homeostasis – intracellular	Ryr2	1.00	0.13	0.95	0.20	0.69	0.04	0.93	0.18
	Ryr3	1.00	0.25	2.07	1.33	0.79	0.25	2.08	0.25
	Atp2a2	1.00	0.17	1.21	0.11	0.68	0.11	0.75	0.03
	Slc8a1	1.00	0.10	2.16	0.72	0.85	0.07	0.96	0.07
	Casq2	1.00	0.10	1.00	0.21	0.84	0.10	0.92	0.03
Ion channels relating to repolarisation	Kcna4	1.00	0.14	0.67	0.08	0.79	0.08	0.80	0.19
	Kcnd3	1.00	0.31	0.78	0.13	0.62	0.06	0.82	0.23
	Kcnh2	1.00	0.23	0.69	0.14	0.73	0.07	0.64	0.07
	Kcnn1	1.00	0.22	0.94	0.27	0.66	0.07	0.88	0.13
	Kcnn2	1.00	0.08	1.06	0.14	1.08	0.09	0.70	0.12
	Kcnk3	1.00	0.18	1.45	0.13	0.86	0.16	1.05	0.13
	Kcne11	1.00	0.28	0.60	0.16	0.47	0.02	0.66	0.39
Adrenergic and cholinergic receptors	Chrm2	1.00	0.17	1.49	0.26	0.79	0.05	0.87	0.08
	Adra1a	1.00	0.21	1.37	0.56	0.75	0.15	1.27	0.38
	Adra1b	1.00	0.05	0.87	0.15	0.67	0.06	0.91	0.12
	Adra1d	1.00	0.27	1.23	0.48	0.48	0.09	0.84	0.12
	Adrb1	1.00	0.24	0.75	0.21	0.72	0.10	0.73	0.15
The cAMP pathway	Adrb2	1.00	0.27	0.86	0.19	0.89	0.18	0.52	0.06
	Adcy4	1.00	0.07	0.79	0.10	0.86	0.09	0.98	0.13
	Adcy5	1.00	0.23	0.82	0.11	0.95	0.20	1.09	0.12
	Pde2a	1.00	0.18	0.99	0.14	0.79	0.16	0.86	0.20
	Pde4d	1.00	0.09	0.67	0.04	0.80	0.11	0.82	0.22
	Prkaca	1.00	0.18	0.79	0.06	0.68	0.12	0.80	0.15
	Prkar1a	1.00	0.17	0.74	0.05	0.76	0.16	0.82	0.09
	Prkar2a	1.00	0.14	0.79	0.15	0.72	0.08	0.78	0.07
	Prkar2b	1.00	0.23	4.84	2.44	1.46	0.65	5.75	4.94
	Camk2d	1.00	0.08	1.35	0.25	1.06	0.07	1.09	0.04

(Continued)

TABLE 1 | Continued

	gene	WT		WT		<i>Pgc-1<math>\beta</math></i> <sup>-/-</sup>		<i>Pgc-1<math>\beta</math></i>	
		Young		Old		Young		Old	
		mean	+/- sem	mean	+/- sem	mean	+/- sem	mean	+/- sem
Fibrotic markers	<i>Tgfb1</i>	1.00	0.15	0.79	0.15	0.69	0.06	0.80	0.18
	<i>Gjd3</i>	1.00	0.45	0.46	0.04	0.62	0.33	0.88	0.26
	<i>Col1a1</i>	1.00	0.09	0.55	0.09	0.70	0.15	0.55	0.05
	<i>Col3a1</i>	1.00	0.16	1.31	0.07	0.78	0.24	0.88	0.15
Other genes	<i>Tbx3</i>	1.00	0.17	0.74	0.05	0.46	0.12	1.05	0.16
	<i>Myh6</i>	1.00	0.17	0.63	0.11	0.66	0.09	0.73	0.12
	<i>Nppa</i>	1.00	0.13	1.12	0.21	0.95	0.08	0.92	0.10
	<i>Trpc1</i>	1.00	0.24	1.67	0.15	1.12	0.32	1.49	0.33
	<i>Ppargc1a</i>	1.00	0.03	1.55	0.13	1.30	0.10	1.05	0.10
	<i>Ppargc1b</i>	1.00	0.15	0.77	0.21	0.00	0.00	0.00	0.00

between cellular compartments, there were neither independent nor interacting effects on transcription of ryanodine receptor isoforms RyR2 (*Ryr2*) and RyR3 (*Ryr3*), the principal cardiac Na<sup>+</sup>-Ca<sup>2+</sup> exchanger (*Slc8a1*), and cardiac SR Ca<sup>2+</sup> binding protein (*Casq2*). However, there was a significant effect of genotype upon the transport mediating Ca<sup>2+</sup>-ATPase (*Atp2a2*).


The two-way ANOVA revealed no significant effects bearing on (6) transcription on voltage dependent K<sup>+</sup> channels underlying AP recovery, including voltage sensitive transient outward current I<sub>to</sub>, Kv1.4 (*Kcna4*), and Kv4.3 (*Kcnd3*), rapid K<sup>+</sup> current, I<sub>Kr</sub>, Kv11.1 (*Kcnh2*), the recently characterized Ca<sup>2+</sup>-activated K<sup>+</sup> channel K<sub>Ca</sub>2.1 (*Kcnn1*) and K<sub>Ca</sub>2.2 (*Kcnn2*) that have a selective atrial as opposed to ventricular occurrence thought to contribute to AP (Xu et al., 2003). This was also the case for the two-predomain TWIK-related acid-sensitive potassium channel 1, TASK-1/K 2P 3.1 (*Kcnk3*) (Olschewski et al., 2017) and the regulatory KCNE1 subunit (*Kcne11*).

Of (7) receptor proteins related to cardiomyocyte cholinergic and adrenergic autonomic activation, the two-way ANOVA detected an independent effect of genotype decreasing muscarinic M<sub>2</sub> (*Chrm2*) expression. There were no effects upon the three cardiac,  $\alpha_{1A}$ ,  $\alpha_{1B}$ , and  $\alpha_{1D}$  (*Adra1a*, *Adra1b*, and *Adra1d*) adrenergic receptor subtypes, thought to protect against pathological remodeling in heart failure (O'Connell et al., 2013) or  $\beta_1$  and  $\beta_2$ - adrenergic receptor subtypes (*Adrb1* and *Adrb2*). The two-way ANOVA detected no effects on transcription of (8) cyclic AMP-dependent cellular messenger pathways involved in such autonomic signaling of which we explored cardiac adenylyl cyclase, types 4 and 5 (*Adcy4* and *Adcy5*), of which type 5 accentuates cardiomyopathic changes on chronic catecholamine stimulation, cGMP-dependent and cAMP-specific 3',5'-cyclic phosphodiesterases 2A and 4D (*Pde2a* and *Pde4d*), and the protein kinase A catalytic  $\alpha$ -subunit (*Prkaca*). We did not observe altered transcription in cardiac Ca<sup>2+</sup>/calmodulin-dependent protein kinase, type II- $\delta$  (*Camk2d*) (Zhang et al., 2004).

The only alterations suggested for markers for (9) atrial fibrosis, concerned independent effects of age in reducing *Colla1*, the major component of type I collagen, the fibrillar collagen

found in most connective tissues. Transcription of the remaining cytokine transforming growth factor  $\beta$  (TGF- $\beta$ 1; *Tgfb1*) (Hao et al., 2011), connexin mCx30.2 (*Gjd3*) (Kreuzberg et al., 2005), and the collagen precursor for the collagen type III  $\alpha$ 1 chain (*Col3a1*) (Davies et al., 2014) were largely unchanged. The final set of genes tested are thought to act as (10) markers for a range of developmental, inflammatory and hypertrophic changes ultimately impacting AP generation and propagation, as well as the genes encoding *Pgc-1 $\beta$*  itself and the complementary *Pgc-1 $\alpha$* . Translation of both the transcriptional repressor known to affect particular components of the cardiac conduction system, *Tbx3* (Sylva et al., 2014), and the major thick filament protein *Myh6* (MHC- $\alpha$ ) whose mutations are associated with late-onset hypertrophic cardiomyopathy, atrial septal defects and sinus node disorder (Huang, 2017). Mutations in atrial natriuretic peptide (*Nppa*) have been implicated in familial AF (Perrin and Gollob, 2012). The non-specific ion channel *Trpc1* conducts both Ca<sup>2+</sup> and Na<sup>+</sup> with Ca<sup>2+</sup> store depletion or activation of the phospholipase C system with associations with hypertrophic change showed increases in groups relative to young WT (Xu and Beech, 2001). The two-way ANOVA did not demonstrate any effects of age or genotype apart from interacting effects on the gene *Pgc-1 $\alpha$*  gene known to complement the function of *Pgc-1 $\beta$* <sup>-/-</sup> and on the gene *Tbx3*.


Figures 2–5 display volcano plots derived from statistical assessments of transcriptional differences in individual genes between atria from young and aged, WT and *Pgc-1 $\beta$* <sup>-/-</sup> mice stratified by *P*-values (<0.01, <0.05 and <0.10, respectively) and plotted against their effect sizes. Comparisons were made between young *Pgc-1 $\beta$* <sup>-/-</sup> and young WT (Figure 2), the effects of aging in WT (Figure 3) and *Pgc-1 $\beta$* <sup>-/-</sup> (Figure 4), respectively, and the eventual differences between aged *Pgc-1 $\beta$* <sup>-/-</sup> and aged WT (Figure 5). They thus provide graphical indications as to where the significant paired differences were to be found, plotting the data points in their entirety over the full range of their *P*-values, and identifying genes where they had *P* < 0.1. In all these comparisons, there were no alterations in transcription of genes bearing on Nav1.5, L or T-type Ca<sup>2+</sup> channel, Ca<sup>2+</sup> homeostasis, or repolarizing K<sup>+</sup> channel function.



**FIGURE 1 |** Heatmap visualizing differential expression between the sample groups grouped by electrophysiological function at the individual gene level combined with two-way ANOVA results examining for independent and interacting effects of *Pgc-1 $\beta$* <sup>-/-</sup> genotype and age. All fold changes normalized to the mean of the expression in samples from young WT hearts. The heatmap is coded yellow for no change, red for increased and green for decreased in fold gene transcription.

This was with the exception of *Atp2a2* in **Figure 5**, and *Ryr3* in **Figure 4**. Of the remaining genes analyzed:

- (1) Compared to young WT hearts, young *Pgc-1 $\beta$* <sup>-/-</sup> demonstrated ( $P < 0.05$ ) reduced transcription in the following genes concerned with resting potential maintenance (**Figure 2**): inwardly rectifying Kir6.1 (*Kcnj8*) and regulatory subunits of the ATP-sensitive K<sup>+</sup> channel 9 (*Abcc9*). There was also a small though significant *Ppargc1a* increase suggesting a compensation for the reduced *Ppargc1b* transcription. Of genes bearing on activation of electrophysiological activity, *Scn7a*, but not the principal *Scn5a* isoform, showed altered transcription. Of molecules underlying intracellular Ca<sup>2+</sup> homeostasis, the trend ( $P < 0.1$ ) toward reduced cardiac RyR2-Ca<sup>2+</sup> SR channel (*Ryr2*) transcription was in a direction contrasting with previously reported increased SR Ca<sup>2+</sup> release phenotypes (Gurung et al., 2011). Patterns of  $\beta$ -adrenergic receptor subtype transcription showed no change, in contrast with the previously reported chronotropic incompetence associated with *Pgc-1 $\beta$* <sup>-/-</sup> (Lelliott et al., 2006). Similarly, there were no alterations in markers for fibrotic change (*Tgfb1*, *Gjd3*, *Col1a1*, and *Col3a1*), although there was a reduced transcription of  $\alpha_{1B}$ -adrenergic receptor subtypes (*Adra1b*) known to mediate protective and adaptive functions preventing pathological remodeling in cardiac failure through Gq/11 signaling (O'Connell et al., 2013) and of the transcriptional repressor *Tbx3*. There was increased transcription of the complementary *Pgc-1 $\alpha$*  (*Ppargc1a*) involved in adjustments to altered metabolic demand.
- (2) **Figure 3** explores the effects of aging in WT atria. There was again a *Ppargc1a* increase compensating for the reduced *Ppargc1b* transcription. In contrast to the comparisons between young *Pgc-1 $\beta$* <sup>-/-</sup> and young WT, aging increased ( $P < 0.05$ ) transcription of the ATP-sensitive K<sup>+</sup> channel 9 regulatory subunit (*Abcc9*), concerned with resting potential maintenance. The trend toward reduced transcription in HCN channels only concerned *Hcn1* rather than the principal *Hcn4* isoform. A decreased *Pde4d* proved to be exclusive to the WT mice, and consequently had not been detected when analyzed with the *Pgc-1 $\beta$* <sup>-/-</sup> in the ANOVA. However, there were no changes concerning Nav1.5, molecules related to L or T-type Ca<sup>2+</sup> channel function or repolarising K<sup>+</sup> channels, or of RyR2 or other molecules controlling intracellular Ca<sup>2+</sup> homeostasis. There was increased transcription of the complementary *Pgc-1 $\alpha$*  (*Ppargc1a*) involved in adjustments to altered metabolic demand. Transcription of the *Col1a1* marker for fibrotic change was reduced. There was a trend toward decreased transcription of TRPC channels involved in signaling cascades mediating cardiac hypertrophy and remodeling (Eder and Molkenin, 2011; Freichel et al., 2017) was increased.
- (3) **Figure 4** illustrates effects of aging in *Pgc-1 $\beta$* <sup>-/-</sup> suggestive of particular effects of *Pgc-1 $\beta$* <sup>-/-</sup> on age-related remodeling changes. Aging *Pgc-1 $\beta$* <sup>-/-</sup> showed features




not shown by aging WT: there was increased transcription of the RyR3 ryanodine receptor isoform (*Ryr3*) and *Tbx3*, and trends toward increased transcription of the principal HCN4 variant of the channels concerned with sinoatrial pacemaker current. There was also trends toward decreased transcription of *KCa2.2* (*Kcnn2*) and increased transcription of adrenergic receptor subtype *Adra1d*, thought to protect against pathological remodeling in heart failure. Aging *Pgc-1 $\beta$* <sup>-/-</sup> did not show the decreased translation of *Coll1a1* or *Abcc9* in contrast to aging WT.

- (4) **Figure 5** compares transcriptional profiles in aged *Pgc-1 $\beta$* <sup>-/-</sup> with those of aged WT constituting the end situations arising from the processes represented in **Figures 3, 4**. This revealed a *Ppargc1a* decrease in contrast to its increase in some of the remaining comparisons.

In aged *Pgc-1 $\beta$* <sup>-/-</sup> compared to aged WT, there was a markedly increased transcription of the principal *Hcn4* isoform concerned with sinoatrial pacemaker current and decreased transcription of the SR  $\text{Ca}^{2+}$ -ATPase subunit *Atp2a2* and of *Pgc-1 $\alpha$*  (*Ppargc1a*). There were trends toward decreased transcription of the type I collagen marker *Col3a1*, TWIK-related acid-sensitive potassium channel 1 (*Kcnk3*), the ATP-sensitive  $\text{K}^{+}$  channel 9 (*Abcc9*), and the cholinergic M2 receptor (*Chrm2*).

## DISCUSSION


The present studies applied quantitative PCR to explore for age-dependent transcriptional changes in genes strategic



to electrophysiological phenotypes underlying atrial pro-arrhythmic tendency in murine hearts deficient in the transcriptional coactivator peroxisome proliferator activated receptor- $\gamma$  coactivator-1 $\beta$  (PGC-1 $\beta$ ). *Pgc-1 $\beta$* <sup>-/-</sup> hearts have proved useful experimental models in studies of atrial arrhythmogenic mechanisms associated with clinical conditions arising from energetic, particularly mitochondrial, functional deficiencies. Of these, the most widespread are atrial arrhythmias, particularly AF for which age and metabolic factors constitute major risk factors through their associations with mitochondrial dysfunction and its associated impaired oxidative capacity (Vianna et al., 2006). *Pgc-1 $\alpha$*  and *Pgc-1 $\beta$*  offer potential therapeutic targets. The PPAR- $\alpha$  agonist fenofibrate, inhibited atrial metabolic remodeling in AF (Liu W.Y. et al., 2016; Zhao et al., 2016). Rosiglitazone reduced atrial interstitial fibrosis and AF promotion in diabetic rabbits by modulating oxidative stress and inflammation (Lin et al., 2014). The specific PPAR $\gamma$  ligands the thiazolidinediones (TZDs) improve clinical insulin sensitivity in type 2 diabetes mellitus (Liu A. et al., 2016). They may also decrease myocardial fibrosis and improve cardiac function (Liu A. et al., 2016).

Recent electrophysiological studies had demonstrated age-dependent atrial arrhythmic phenotypes in murine *Pgc-1 $\beta$* <sup>-/-</sup> hearts relating these to abnormal electrophysiological properties, Ca<sup>2+</sup> homeostasis and fibrotic change (Valli et al., 2017a,b, 2018a; Ahmad et al., 2018). The present quantitative PCR studies went on to explore for altered transcription of genes selected to encode the ion channels, other transport proteins, markers for autonomic and energetic function and developmental, inflammatory, and fibrotic and hypertrophic changes that may underly those reported physiological changes. It was therefore possible to determine whether the electrophysiological differences (Valli et al., 2017a,b, 2018a; Ahmad et al., 2018) correlated with correspondingly altered patterns of protein transcriptional change, or otherwise. Whilst not distinguishing surface from internal membrane protein expression, they revealed differing patterns of transcriptional change in proteins related to each process. This approach had previously successfully been applied to studies in rat as opposed to genetically modified mouse hearts (Atkinson et al., 2013). Thus the previous electrophysiological studies in young and old, WT and *Pgc-1 $\beta$* <sup>-/-</sup>, hearts reported:






(1) Impaired sino-atrial pacing and negative dromotropic responses suggesting defective atrioventricular conduction following adrenergic activation particularly in intact aged *Pgc-1 $\beta$* <sup>-/-</sup> mice (Ahmad et al., 2018) and impaired chronotropic responses to adrenergic stimulation (Lelliott et al., 2006). In contrast, 2-way ANOVA detected no significant differences between groups in transcription of autonomic  $\beta$ -adrenergic receptors, but did detect genotypic effects decreasing the cholinergic *Chrm2*. There were no differences in HCN4 transcription mediating pacemaker currents. Differences suggested by the volcano plots did not bear on  $\beta$ -adrenergic responses; young *Pgc-1 $\beta$* <sup>-/-</sup> showing lower *Adra1b* expression than young WT, and old WT showing lower *Pde4d* expression than young WT. Aged *Pgc-1 $\beta$* <sup>-/-</sup> showed increased *Hcn4* expression compared to aged WT, contrasting with the compromised SAN response to adrenergic challenge shown by *Pgc-1 $\beta$* <sup>-/-</sup>.

In intact Langendorff-perfused hearts, there were (2) similar resting potentials between experimental groups (Valli et al., 2017b). Yet markers for molecules concerned with resting potential generation indicated reduced transcription in several genes related to resting potential. The two-way ANOVA demonstrated that the *Pgc-1 $\beta$* <sup>-/-</sup> genotype decreased the

markers of Na<sup>+</sup>-K<sup>+</sup>-ATPase transcription *Atp1a1*, *ATP1a2*, and *Atp1b1*, and those of the K<sup>+</sup> channels *Abcc9* and *Kcnj8*. The volcano plots indicated that young *Pgc-1 $\beta$* <sup>-/-</sup> showed reduced *Abcc9* and *Kcnj8* relative to young WT, and aged WT, increased *Abcc9* relative to young WT.

(3)-(6) *Pgc-1 $\beta$* <sup>-/-</sup> showed (3) age-dependent slowing of AP conduction associated with reduced AP upstroke rates (dV/dt)<sub>max</sub> implicating reduced Na<sup>+</sup> channel function (Valli et al., 2017a). In contrast, (4) AP repolarization rates reflected in action potential durations (APDs) remained similar between experimental groups (Valli et al., 2017b). Loose-patch clamp studies related the above findings to (5) reduced depolarizing, Na<sup>+</sup>, but (6) normal repolarizing voltage-dependent and inward rectifier K<sup>+</sup> current in both young and aged *Pgc-1 $\beta$* <sup>-/-</sup> genotype (Valli et al., 2018a). In contrast to (3) and (5), both two-way ANOVA and volcano plots demonstrated no differences between groups for Nav1.5 (*Scn5a*), or surface L- or T-type Ca<sup>2+</sup> channel related genes relevant to initiation or maintenance of AP depolarization. However, in accord with (4) and (6), markers for voltage-dependent K<sup>+</sup> channels underlying AP repolarization duration were indistinguishable between groups culminating in indistinguishable outcomes between aged *Pgc-1 $\beta$* <sup>-/-</sup> and aged WT.



Finally, *Pgc-1 $\beta$ <sup>-/-</sup>* was associated with (7) *Ca<sup>2+</sup> homeostatic changes* reflected in diastolic SR *Ca<sup>2+</sup>* release events, altered *Ca<sup>2+</sup>* current characteristics and consequent early and delayed afterdepolarization phenomena (Gurung et al., 2011). In contrast, both two-way ANOVA and the volcano plots revealed no systematic changes in markers for *Ca<sup>2+</sup>* homeostatic change mediating RyR2 (*Ryr2*), *Na<sup>+</sup>/Ca<sup>2+</sup>* exchange (*Slc8a1*) or calsequestrin (*Casq2*). However, there were independent genotypic effects on sarcoplasmic reticular *Ca<sup>2+</sup>* ATPase (*Atp2a2*). These manifested as diminished *Atp2a2* transcription in old *Pgc-1 $\beta$ <sup>-/-</sup>* compared to aged WT (but not young

*Pgc-1 $\beta$ <sup>-/-</sup>*) hearts, with increased expression of *Ryr3* (but not *Ryr2*) in old *Pgc-1 $\beta$ <sup>-/-</sup>* compared to young *Pgc-1 $\beta$ <sup>-/-</sup>*.

(8) The *Pgc-1 $\beta$ <sup>-/-</sup>* genotype also was responsible for producing an age-dependent fibrotic change itself contributing to slowed AP conduction (Jeevaratnam et al., 2011). In contrast, both two-way ANOVA and volcano plots demonstrated that age independently reduced expression of *Col1a1* though there were no effects whether independent or interacting of *Pgc-1 $\beta$ <sup>-/-</sup>* in the remaining (*Tgfb1*, *Gjd5*, *Col3a1*) transcription markers. However, young *Pgc-1 $\beta$ <sup>-/-</sup>* showed reduced  $\alpha_{1B}$ -adrenergic receptor (*Adra1b*) transcription compared to young

WT known to mediate protective and adaptive functions preventing pathological remodeling in cardiac failure through Gq/11 signaling (O'Connell et al., 2013). Of examined markers for a range of developmental, inflammatory and hypertrophic changes, two-way ANOVA demonstrated no differences bearing on *Tbx3*, *Myh6*, or *Nppa* although *Tbx3* was increased in aged relative to young *Pgc-1β*<sup>-/-</sup>.

Finally, two way ANOVA demonstrated that both genotype and age independently and interactively exerted transcription changes in the complementary *Pgc-1α* gene (*Ppargc1a*). There was increased transcription in aged WT compared to young WT, and in young *Pgc-1β*<sup>-/-</sup> compared to young WT but decreased transcription in aged *Pgc-1β*<sup>-/-</sup> compared to aged WT.

The present findings together limit roles for transcriptomic changes in the age-dependent pro-arrhythmic phenotypic features of *Pgc-1β*<sup>-/-</sup> to altered Ca<sup>2+</sup>-ATPase (*Atp2a2*) expression. However, this is compatible with a previously reported arrhythmic mechanism demonstrated in p21-activated kinase type 1 deficient hearts on an earlier occasion (Wang et al., 2014; Wang Y. et al., 2015). These could add to contributions from direct physiological consequences of altered mitochondrial dysfunction. Thus the latter increases reactive oxygen species (ROS) production that acutely affects voltage-dependent Na<sup>+</sup> and K<sup>+</sup> channels (Wang et al., 2004; Liu et al., 2010), ryanodine receptors and gap junctions (Terentyev et al., 2008; Brown and O'Rourke, 2010; Sovari et al., 2013). Both transcriptomically and physiologically produced alterations in Ca<sup>2+</sup> homeostasis could reduce Nav1.5 function (King et al., 2013; Ning et al., 2016), in turn associated with increased TGF-β activity, fibrotic change (Brooks and Conrad, 2000; Rosenkranz et al., 2002; Dai et al., 2009; Hafner et al., 2010; Hao et al., 2011), and disrupted gap junction function (van Veen et al., 2005; Chilton et al., 2007; Xie

et al., 2009). Both Nav1.5 and gap junction changes may contribute pro-arrhythmic conduction changes observed in *Pgc-1β*<sup>-/-</sup> hearts.

## ETHICS STATEMENT

Experiments were approved by the University of Cambridge ethics review board under a United Kingdom project license for studies of cardiac arrhythmia. All procedures complied with the United Kingdom Home Office regulations [Animals (Scientific Procedures) Act 1986]. The experiments also conformed to the Guide for the Care and Use of Laboratory Animals, United States National Institutes of Health (NIH Publication No. 85-23, revised 1996).

## AUTHOR CONTRIBUTIONS

CE, KC, and IF performed the genome transcription studies, HV and SA performed the specimen preparation, CH and KJ conceived and designed the study and wrote the manuscript.

## FUNDING

We thank the Medical Research Council (MR/M001288/1), Wellcome Trust (105727/Z/14/Z), British Heart Foundation (PG/14/79/31102 and PG/15/12/31280), Sudden Adult Death Syndrome (SADS) United Kingdom Society, and the Fundamental Research Grant Scheme (FRGS/2014/SKK01/PERDANA/02/1) (Ministry of Education, Malaysia) for their generous support.

## REFERENCES

- Ahmad, S., Valli, H., Salvage, S., Grace, A., Jeevaratnam, K., and Huang, C. H. (2018). Age-dependent electrocardiographic changes in *Pgc-1β* deficient murine hearts. *Clin. Exp. Pharmacol. Physiol.* 45, 174–186. doi: 10.1111/1440-1681.12863
- Akar, F. G., and O'Rourke, B. (2011). Mitochondria are sources of metabolic sink and arrhythmias. *Pharmacol. Ther.* 131, 287–294. doi: 10.1016/j.pharmthera.2011.04.005
- Arany, Z., He, H., Lin, J., Hoyer, K., Handschin, C., Toka, O., et al. (2005). Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle. *Cell Metab.* 1, 259–271.
- Atkinson, A. J., Logantha, S. J. R. J., Hao, G., Yanni, J., Fedorenko, O., Sinha, A., et al. (2013). Functional, anatomical, and molecular investigation of the cardiac conduction system and arrhythmogenic atrioventricular ring tissue in the rat heart. *J. Am. Heart Assoc.* 2:e000246. doi: 10.1161/JAHA.113.000246
- Brooks, W. W., and Conrad, C. H. (2000). Myocardial fibrosis in transforming growth factor β(1)heterozygous mice. *J. Mol. Cell. Cardiol.* 32, 187–195. doi: 10.1006/jmcc.1999.1065
- Brown, D. A., and O'Rourke, B. (2010). Cardiac mitochondria and arrhythmias. *Cardiovasc. Res.* 88, 241–249. doi: 10.1093/cvr/cvq231
- Chilton, L., Giles, W. R., and Smith, G. L. (2007). Evidence of intercellular coupling between co-cultured adult rabbit ventricular myocytes and myofibroblasts. *J. Physiol.* 583, 225–236. doi: 10.1113/jphysiol.2007.135038
- Dai, D.-F., Santana, L. F., Vermulst, M., Tomazela, D. M., Emond, M. J., MacCoss, M. J., et al. (2009). Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. *Circulation* 119, 2789–2797. doi: 10.1161/CIRCULATIONAHA.108.822403
- Davies, L., Jin, J., Shen, W., Tsui, H., Shi, Y., Wang, Y., et al. (2014). Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age. *J. Am. Heart Assoc.* 3:e000340. doi: 10.1161/JAHA.113.000340
- Eder, P., and Molkenin, J. D. (2011). TRPC channels as effectors of cardiac hypertrophy. *Circ. Res.* 108, 265–272. doi: 10.1161/CIRCRESAHA.110.225888
- Freichel, M., Berlin, M., Schürger, A., Mathar, I., Bacmeister, L., Medert, R., et al. (2017). "TRP channels in the heart," in *Neurobiology of TRP Channels*, ed. T. Emir (Baton Roca, FL: CRC Press/Taylor & Francis).
- Gurung, I., Medina-Gomez, G., Kis, A., Baker, M., Velagapudi, V., Neogi, S. G., et al. (2011). Deletion of the metabolic transcriptional coactivator PGC1β induces cardiac arrhythmia. *Cardiovasc. Res.* 92, 29–38. doi: 10.1093/cvr/cvr155
- Hafner, A. V., Dai, J., Gomes, A. P., Xiao, C.-Y., Palmeira, C. M., Rosenzweig, A., et al. (2010). Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. *Aging* 2, 914–923. doi: 10.18632/aging.100252
- Hao, X., Zhang, Y., Zhang, X., Nirmalan, M., Davies, L., Constantinou, D., et al. (2011). TGF-β1-mediated fibrosis and ion channel remodeling are key mechanisms in producing the sinus node dysfunction associated with SCN5A deficiency and aging. *Circ. Arrhythm. Electrophysiol.* 4, 397–406. doi: 10.1161/CIRCEP.110.960807

- Ho, J. E., Rahban, Y., Sandhu, H., Hiremath, P. G., Ayalon, N., Qin, F., et al. (2017). Preclinical alterations in myocardial microstructure in people with metabolic syndrome. *Obesity* 25, 1516–1522. doi: 10.1002/oby.21936
- Huang, C. L. H. (2017). Murine electrophysiological models of cardiac arrhythmogenesis. *Physiol. Rev.* 97, 283–409. doi: 10.1152/physrev.00007.2016
- Jeevaratnam, K., Poh Tee, S., Zhang, Y., Rewbury, R., Guzadhur, L., Duehmke, R., et al. (2011). Delayed conduction and its implications in murine *Scn5a*+/- hearts: independent and interacting effects of genotype, age, and sex. *Pflügers Arch. Eur. J. Physiol.* 461, 29–44. doi: 10.1007/s00424-010-0906-1
- King, J., Wickramarachchi, C., Kua, K., Du, Y., Jeevaratnam, K., Matthews, H. R., et al. (2013). Loss of *Nav1.5* expression and function in murine atria containing the *RyR2-P2328S* gain-of-function mutation. *Cardiovasc. Res.* 99, 751–759. doi: 10.1093/cvr/cvt141
- Komen, J. C., and Thorburn, D. R. (2014). Turn up the power - Pharmacological activation of mitochondrial biogenesis in mouse models. *Br. J. Pharmacol.* 171, 1818–1836. doi: 10.1111/bph.12413
- Kreuzberg, M. M., Söhl, G., Kim, J. S., Verselis, V. K., Willecke, K., and Bukauskas, F. F. (2005). Functional properties of mouse *connexin30.2* expressed in the conduction system of the heart. *Circ. Res.* 96, 1169–1177. doi: 10.1161/01.RES.0000169271.33675.05
- Krishnan, K. J., Greaves, L. C., Reeve, A. K., and Turnbull, D. (2007). The ageing mitochondrial genome. *Nucleic Acids Res.* 35, 7399–7405. doi: 10.1093/nar/gkm635
- Lelliott, C. J., Medina-Gomez, G., Petrovic, N., Kis, A., Feldmann, H. M., Bjursell, M., et al. (2006). Ablation of *PGC-1beta* results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. *PLoS Biol.* 4:e369. doi: 10.1371/journal.pbio.0040369
- Lin, C. F., Young, K. C., Bai, C. H., Yu, B. C., Ma, C. T., Chien, Y. C., et al. (2014). Rosiglitazone regulates anti-inflammation and growth inhibition via *PTEN*. *Biomed Res. Int.* 2014:787924. doi: 10.1155/2014/787924
- Liu, A., Kim, S. H., Ariel, D., Abbasi, F., Lamendola, C., Cardell, J., et al. (2016). Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study. *Sleep Med.* 22, 57–60. doi: 10.1016/j.sleep.2016.06.005
- Liu, W. Y., Tzeng, T. F., and Liu, I. M. (2016). Zerumbone, a bioactive sesquiterpene, ameliorates diabetes-induced retinal microvascular damage through inhibition of phospho-p38 mitogen-activated protein kinase and nuclear factor- $\kappa$ B pathways. *Molecules* 21:1708. doi: 10.3390/molecules21121708
- Liu, M., Liu, H., and Dudley, S. C. (2010). Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. *Circ. Res.* 107, 967–974. doi: 10.1161/CIRCRESAHA.110.220673
- Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* 25, 402–408. doi: 10.1006/meth.2001.1262
- Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P., et al. (2006). Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 114, 119–125. doi: 10.1161/CIRCULATIONAHA.105.595140
- Nichols, C. G. (2006). KATP channels as molecular sensors of cellular metabolism. *Nature* 440, 470–476. doi: 10.1038/nature04711
- Ning, F., Luo, L., Ahmad, S., Valli, H., Jeevaratnam, K., Wang, T., et al. (2016). The *RyR2-P2328S* mutation downregulates *Nav1.5* producing arrhythmic substrate in murine ventricles. *Pflügers Arch. Eur. J. Physiol.* 468, 655–665. doi: 10.1007/s00424-015-1750-0
- O'Connell, T. D., Jensen, B. C., Baker, A. J., and Simpson, P. C. (2013). Cardiac alpha-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. *Pharmacol. Rev.* 66, 308–333. doi: 10.1124/pr.112.007203
- Olschewski, A., Veale, E. L., Nagy, B. M., Nagaraj, C., Kwapiszewska, G., Antigny, F., et al. (2017). *TASK-1 (KCNK3)* channels in the lung: from cell biology to clinical implications. *Eur. Respir. J.* 50, 1700754. doi: 10.1183/13993003.00754-2017
- Perrin, M. J., and Gollob, M. H. (2012). The role of atrial natriuretic peptide in modulating cardiac electrophysiology. *Hear. Rhythm* 9, 610–615. doi: 10.1016/j.hrthm.2011.11.019
- Rosenkranz, S., Fleisch, M., Amann, K., Haeuseler, C., Kilter, H., Seeland, U., et al. (2002). Alterations of  $\beta$ -adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing *TGF- $\beta$  1*. *Am. J. Physiol. Hear. Circ. Physiol.* 283, H1253–H1262. doi: 10.1152/ajpheart.00578.2001
- Russo, L., and Frangogiannis, N. G. (2016). Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. *J. Mol. Cell. Cardiol.* 90, 84–93. doi: 10.1016/j.yjmcc.2015.12.011
- Scheuermann-Freestone, M., Madsen, P. L., Manners, D., Blamire, A. M., Buckingham, R. E., Styles, P., et al. (2003). Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. *Circulation* 107, 3040–3046. doi: 10.1161/01.CIR.0000072789.89096.10
- Sonoda, J., Mehl, I. R., Chong, L.-W., Nofsinger, R. R., and Evans, R. M. (2007). *PGC-1beta* controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. *Proc. Natl. Acad. Sci. U.S.A.* 104, 5223–5228. doi: 10.1073/pnas.0611623104
- Sovari, A. A., Rutledge, C. A., Jeong, E.-M., Dolmatova, E., Arasu, D., Liu, H., et al. (2013). Mitochondria oxidative stress, connexin-43 remodeling, and sudden arrhythmic death. *Circ. Arrhythm. Electrophysiol.* 6, 623–631. doi: 10.1161/CIRCEP.112.976787
- Sylva, M., Van den Hoff, M. J. B., and Moorman, A. F. M. (2014). Development of the human heart. *Am. J. Med. Genet. Part A* 164, 1347–1371. doi: 10.1002/ajmg.a.35896
- Terentyev, D., Gyorke, I., Belevych, A. E., Terentyeva, R., Sridhar, A., Nishijima, Y., et al. (2008). Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum  $Ca^{2+}$  leak in chronic heart failure. *Circ. Res.* 103, 1466–1472. doi: 10.1161/CIRCRESAHA.108.184457
- Thollon, C., Bedut, S., Villeneuve, N., Cogé, F., Piffard, L., Guillaumin, J. P., et al. (2007). Use-dependent inhibition of *hHCN4* by ivabradine and relationship with reduction in pacemaker activity. *Br. J. Pharmacol.* 150, 37–46. doi: 10.1038/sj.bjp.0706940
- Valli, H., Ahmad, S., Chadda, K., Al-Hadithi, A., Grace, A., Jeevaratnam, K., et al. (2017a). Age-dependent atrial arrhythmic phenotype secondary to mitochondrial dysfunction in *Pgc-1 $\beta$*  deficient murine hearts. *Mech. Ageing Dev.* 167, 30–45. doi: 10.1016/j.mad.2017.09.002
- Valli, H., Ahmad, S., Fraser, J. A., Jeevaratnam, K., and Huang, C. L. H. (2017b). Pro-arrhythmic atrial phenotypes in incrementally paced murine *Pgc1 $\beta$* -/- hearts: effects of age. *Exp. Physiol.* 102, 1619–1634. doi: 10.1113/EP086589
- Valli, H., Ahmad, S., Jiang, A. Y., Smyth, R., Jeevaratnam, K., Matthews, H. R., et al. (2018a). Cardiomyocyte ionic currents in intact young and aged murine *Pgc-1 $\beta$* -/- atrial preparations. *Mech. Ageing Dev.* 169, 1–9. doi: 10.1016/j.mad.2017.11.016
- Valli, H., Ahmad, S., Sriharan, S., Dean, L. D., Grace, A. A., Jeevaratnam, K., et al. (2018b). Epac-induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes. *Clin. Exp. Pharmacol. Physiol.* 45, 278–292. doi: 10.1111/1440-1681.12870
- van Veen, T. A. B., Stein, M., Royer, A., Le Quang, K., Charpentier, F., Colledge, W. H., et al. (2005). Impaired impulse propagation in *Scn5a*-knockout mice: combined contribution of excitability, connexin expression, and tissue architecture in relation to aging. *Circulation* 112, 1927–1935. doi: 10.1161/CIRCULATIONAHA.105.539072
- Vianna, C. R., Huntgeburth, M., Coppari, R., Choi, C. S., Lin, J., Krauss, S., et al. (2006). Hypomorphic mutation of *PGC-1 $\beta$*  causes mitochondrial dysfunction and liver insulin resistance. *Cell Metab.* 4, 453–464. doi: 10.1016/j.cmet.2006.11.003
- Villena, J. A. (2015). New insights into *PGC-1* coactivators: redefining their role in the regulation of mitochondrial function and beyond. *FEBS J.* 282, 647–672. doi: 10.1111/febs.13175
- Wang, J., Wang, H., Zhang, Y., Gao, H., Nattel, S., and Wang, Z. (2004). Impairment of *HERG K(+)* channel function by tumor necrosis factor- $\alpha$ : role of reactive oxygen species as a mediator. *J. Biol. Chem.* 279, 13289–13292.
- Wang, X., West, J. A., Murray, A. J., and Griffin, J. L. (2015). A comprehensive metabolic profiling of age-related mitochondrial dysfunction in the high-fat fed *ob/ob* mouse heart. *J. Proteome Res.* 14, 2849–2862. doi: 10.1021/acs.jproteome.5b00128
- Wang, Y., Tsui, H., Bolton, E. L., Wang, X., Huang, C. L.-H., Solaro, R. J., et al. (2015). Novel insights into mechanisms for *Pak1*-mediated regulation of cardiac  $Ca^{2+}$  homeostasis. *Front. Physiol.* 6:76. doi: 10.3389/fphys.2015.00076

- Wang, Y., Tsui, H., Ke, Y., Shi, Y., Li, Y., Davies, L., et al. (2014). Pak1 is required to maintain ventricular Ca(2+) homeostasis and electrophysiological stability through SERCA2a regulation in mice. *Circ. Arrhythm. Electrophysiol.* 7, 938–948. doi: 10.1161/CIRCEP.113.001198
- Xie, Y., Garfinkel, A., Camelliti, P., Kohl, P., Weiss, J. N., and Qu, Z. (2009). Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: a computational study. *Heart Rhythm* 6, 1641–1649. doi: 10.1016/j.hrthm.2009.08.003
- Xu, S.-Z., and Beech, D. J. (2001). TrpC1 is a membrane-spanning subunit of store-operated Ca2+ channels in native vascular smooth muscle cells. *Circ. Res.* 88, 84–87. doi: 10.1161/01.RES.88.1.84
- Xu, Y., Tuteja, D., Zhang, Z., Xu, D., Zhang, Y., Rodriguez, J., et al. (2003). Molecular identification and functional roles of a Ca(2+)-activated K+ channel in human and mouse hearts. *J. Biol. Chem.* 278, 49085–49094. doi: 10.1074/jbc.M307508200
- Zhang, T., Miyamoto, S., and Brown, J. H. (2004). Cardiomyocyte calcium and calcium/calmodulin-dependent protein kinase II: friends or foes? *Recent Prog. Horm. Res.* 59, 141–168. doi: 10.1210/rp.59.1.141
- Zhao, J., Liu, G. Z., Hou, T. T., Yuan, Y., Hang, P. Z., Zhao, J. J., et al. (2016). Fenofibrate inhibits atrial metabolic remodeling in atrial fibrillation through PPAR- $\alpha$ /sirtuin 1/PGC-1 $\alpha$  pathway. *Br. J. Pharmacol.* 173, 1095–1109. doi: 10.1111/bph.13438

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Edling, Fazmin, Chadda, Ahmad, Valli, Huang and Jeevaratnam. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.